Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion

News provided by

May 10, 2012, 06:32 ET

NEW YORK, May 10, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion

http://www.reportlinker.com/p0850353/Cytotoxic-Therapies-Market-to-2017---Launch-of-Next-Generation-Camptothecin-Analogues-Will-Help-Offset-Revenue-Loss-due-to-Generic-Erosion.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion

Summary Europe Japan

In 2010, the cytotoxic therapies market for eight major oncology indications was estimated at $10.1 billion, indicating a compound annual growth rate (CAGR) of 5.8% since 2002. GBI Research forecasts the market to decline marginally at a CAGR of (0.1%) between 2010 and 2017, to record a sales value of $10.1 billion by 2017. The eight indications covered are breast cancer, cervical cancer, colorectal cancer, head and neck cancer, non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer, and prostate cancer. The growth in major markets such as the US, the top five countries of Europe, and Japan, was driven mainly by the increasing prevalence and prescription population, and the combination of cytotoxic medicines with biologics, while the overall decline in market value is a result of patent expiries in the forecast period and subsequent reduction in annual cost of therapy.

The US was the leading geography, with an estimated sales value of $5.5 billion and an approximate share of 55%. The US market is expected to decline at a rate of (1.7%) between 2010 and 2017, to record a sales value of $4.9 billion in 2017. The top five countries of Europe together contributed to sales worth $3.3 billion in 2010, accounting for an approximate global share of 32.4%. The top five countries of Europe are expected to record sales worth $3.8 billion by the year 2017, registering a growth rate of 2%. Japan, in 2010, contributed $1.3 billion to the global market, increasing at a CAGR of 4.5% from 2002. It accounts for an approximate share of 12.6%. Decreasing at a rate of (1.1%) between 2010 and 2017, the market is expected to record sales worth $1.2 billion by 2017.

Scope Germany France Italy Spain Japan

- Annualized market data for the cytotoxic therapies market from 2002 to 2010, with forecasts to 2017.

- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume, and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.

- Key drivers and restraints that have had a significant impact on the market.

- The competitive landscape of the global cytotoxic therapies market, including top companies benchmarking. The key companies studied in this report are Sanofi, Eli Lilly, Takeda Pharmaceuticals and Roche

- Key M&A activities and licensing agreements that took place in 2008 and 2011 in the cytotoxic therapies market.

Reasons to buy

- Build effective strategies to launch their pipeline products by identifying potential geographies.

- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.

- Develop key strategic initiatives by studying the key strategies of top competitors.

- Devise a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.

- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

1 Table of Contents1 Table of Contents 31.1 List of Tables 71.2 List of Figures 112 Cytotoxic Therapies Market to 2017 - Introduction 142.1 GBI Research Report Guidance 153 Cytotoxic Therapies Market to 2017 - Market Overview 163.1 Introduction 163.1.1 Revenue 163.1.2 Annual Cost of Therapy 193.1.3 Treatment Usage Pattern 203.2 Drivers and Barriers for the Global Cytotoxic Therapies Market 223.2.1 Drivers for the Global Cytotoxic Therapies Market 223.2.2 Barriers for the Global Cytotoxic Therapies Market 234 Cytotoxic Therapies Market to 2017 - Geographical Landscape 244.1 Geographical Segmentation 244.2 The US 264.2.1 Revenue 264.2.2 Annual Cost of Therapy 274.2.3 Treatment Usage Pattern 284.2.4 Drivers and Barriers for the Cytotoxic Therapies Market in the US 304.3 Top Five Countries of Europe 324.3.1 Revenue 324.3.2 Annual Cost of Therapy 334.3.3 Treatment Usage Pattern 344.3.4 Drivers and Barriers for the Cytotoxic Therapies Market in the Top Five Countries of Europe 364.4 Japan 384.4.1 Revenue 384.4.2 Annual Cost of Therapy 394.4.3 Treatment Usage Pattern 404.4.4 Drivers and Barriers for the Cytotoxic Therapies Market in Japan 425 Cytotoxic Therapies Market to 2017 - Therapeutic Landscape 445.1 Breast Cancer 445.1.1 Introduction 445.1.2 Survival Rates by Stage 465.1.3 Symptoms 465.1.4 Treatment Flow 475.1.5 Revenue 505.1.6 Annual Cost of Therapy 535.1.7 Treatment Usage Pattern 545.1.8 Drivers and Barriers 565.2 Cervical Cancer 575.2.1 Introduction 575.2.2 Survival Rates 585.2.3 Symptoms 595.2.4 Treatment Flow 595.2.5 Revenue 605.2.6 Annual Cost of Therapy 635.2.7 Treatment Usage Pattern 645.2.8 Drivers and Barriers 665.3 Colorectal Cancer 675.3.1 Introduction 675.3.2 Survival Rates by Stage 685.3.3 Symptoms 685.3.4 Treatment Flow 695.3.5 Revenue 725.3.6 Annual Cost of Therapy 755.3.7 Treatment Usage Pattern 765.3.8 Drivers and Barriers 785.4 Head and Neck Cancer 795.4.1 Introduction 795.4.2 Survival Rates 805.4.3 Symptoms 805.4.4 Treatment Flow 815.4.5 Revenue 825.4.6 Annual Cost of Therapy 865.4.7 Treatment Usage Pattern 875.4.8 Drivers and Barriers 895.5 Non-Hodgkin Lymphoma 905.5.1 Introduction 905.5.2 Survival Rates by Stage 915.5.3 Symptoms 915.5.4 Treatment Flow 925.5.5 Revenue 935.5.6 Annual Cost of Therapy 965.5.7 Treatment Usage Pattern 975.5.8 Drivers and Barriers 995.6 Non-Small Cell Lung Cancer (NSCLC) 1005.6.1 Introduction 1005.6.2 Survival Rates by Stage 1015.6.3 Symptoms 1015.6.4 Treatment Flow 1025.6.5 Revenue 1045.6.6 Annual Cost of Therapy 1075.6.7 Treatment Usage Pattern 1085.6.8 Drivers and Barriers 1105.7 Ovarian Cancer 1115.7.1 Introduction 1115.7.2 Survival Rates 1115.7.3 Symptoms 1125.7.4 Treatment Flow 1125.7.5 Revenue 1135.7.6 Annual Cost of Therapy 1165.7.7 Treatment Usage Pattern 1175.7.8 Drivers and Barriers 1195.8 Prostate Cancer 1205.8.1 Introduction 1205.8.2 Survival Rates 1215.8.3 Symptoms 1215.8.4 Treatment Flow 1225.8.5 Revenue 1235.8.6 Annual Cost of Therapy 1275.8.7 Treatment Usage Pattern 1285.8.8 Drivers and Barriers 1306 Cytotoxic Therapies Market to 2017 - Pipeline Analysis 1316.1 Introduction 1316.2 Cytotoxic Therapies Market - Pipeline Assessment by Indication 1336.2.1 Breast Cancer 1336.2.2 Cervical Cancer 1376.2.3 Colorectal Cancer 1386.2.4 Head and Neck Cancer 1436.2.5 Non-Hodgkin Lymphoma 1466.2.6 Non-Small Cell Lung Cancer 1496.2.7 Ovarian Cancer 1536.2.8 Prostate Cancer 1596.3 Profiles of Promising Molecules in the Cytotoxic Therapies Market 1626.3.1 Eniluracil (ADH300004) 1626.3.2 Karenitecin 1636.3.3 Vintafolide (EC145) 1646.3.4 Tavocept 1657 Cytotoxic Therapies Market to 2017 - Competitive Lanscape 1677.1 Sanofi 1677.1.1 Company Overview 1677.1.2 Marketed Products 1687.1.3 SWOT Analysis 1687.2 Eli Lilly & Company 1697.2.1 Company Overview 1697.2.2 Marketed Products 1707.2.3 SWOT Analysis 1717.3 Takeda Pharmaceutical Company Ltd. 1727.3.1 Company Overview 1727.3.2 Marketed Products 1737.3.3 SWOT Analysis 1737.4 F. Hoffmann-La Roche Ltd. 1747.4.1 Company Overview 1747.4.2 Marketed Products 1757.4.3 SWOT Analysis 1758 Cytotoxic Therapies Market to 2017 - Strategic Consolidations 1768.1 Deals by Type 1768.2 Deals by Indication 1778.3 Mergers and Acquisitions 1788.3.1 Segmentation by Year 1788.3.2 Segmentation by Value 1798.3.3 Segmentation by Geography 1808.3.4 Major Merger and Acquisition Deals 1808.4 Co-Development Deals 1818.4.1 Segmentation by Year 1828.4.2 Segmentation by Geography 1838.4.3 Major Co-Development Deals 1848.5 Licensing Deals 1858.5.1 Segmentation by Year 1868.5.2 Segmentation by Value 1878.5.3 Segmentation by Geography 1888.5.4 Major Licensing Deals 1909 Cytotoxic Therapies Market to 2017 - Appendix 1919.1 Market Definitions 1919.2 Abbreviations 1919.3 Sources 1939.4 Research Methodology 1949.4.1 Coverage 1949.4.2 Secondary Research 1949.4.3 Primary Research 1949.4.4 Therapeutic Landscape 1959.4.5 Market Size by Geography 1979.4.6 Geographical Landscape 1979.4.7 Pipeline Analysis 1989.4.8 Competitive Landscape 1989.4.9 Expert Panel Validation 1989.5 Contact Us 1989.6 Disclaimer 198

1.1 List of Tables

Table 1: Cytotoxic Therapies Market, Global, Revenue ($bn), 2002-2010 16Table 2: Cytotoxic Therapies Market, Global, Revenue Forecasts ($bn), 2010-2017 16Table 3: Cytotoxic Therapies Market, Global, Annual Cost of Therapy ($), 2002-2010 19Table 4: Cytotoxic Therapies Market, Global, Annual Cost of Therapy ($), 2010-2017 19Table 5: Cytotoxic Therapies Market, Global, Treatment Usage Pattern, Population ('000), 2002-2010 20Table 6: Cytotoxic Therapies Market, Global, Treatment Usage Pattern, Population ('000), 2010-2017 21Table 7: Cytotoxic Therapies Market, Global, Geographical Segmentation ($m), 2002-2010 24Table 8: Cytotoxic Therapies Market, Global, Geographical Segmentation ($m), 2010-2017 24Table 9: Cytotoxic Therapies Market, The US, Revenue ($bn), 2002-2010 26Table 10: Cytotoxic Therapies Market, The US, Revenue Forecasts ($bn), 2010-2017 26Table 11: Cytotoxic Therapies Market, The US, Annual Cost of Therapy ($), 2002-2010 27Table 12: Cytotoxic Therapies Market, The US, Annual Cost of Therapy ($), 2010-2017 27Table 13: Cytotoxic Therapies Market, The US, Treatment Usage Pattern, Population ('000), 2002-2010 28Table 14: Cytotoxic Therapies Market, The US, Treatment Usage Pattern, Population ('000), 2010-2017 29Table 15: Cytotoxic Therapies Market, Top Five Countries of Europe, Revenue ($m), 2002-2010 32Table 16: Cytotoxic Therapies Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2010-2017 32Table 17: Cytotoxic Therapies Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2002-2010 33Table 18: Cytotoxic Therapies Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2010-2017 33Table 19: Cytotoxic Therapies Market, Top Five Countries of Europe, Treatment Usage Pattern, Population ('000), 2002-2010 34Table 20: Cytotoxic Therapies Market, Top Five Countries of Europe, Treatment Usage Pattern, Population ('000), 2010-2017 35Table 21: Cytotoxic Therapies Market, Japan, Revenue ($m), 2002-2010 38Table 22: Cytotoxic Therapies Market, Japan, Revenue Forecasts ($m), 2010-2017 38Table 23: Cytotoxic Therapies Market, Japan, Annual Cost of Therapy ($), 2002-2010 39Table 24: Cytotoxic Therapies Market, Japan, Annual Cost of Therapy ($), 2010-2017 39Table 25: Cytotoxic Therapies Market, Japan, Treatment Usage Pattern, Population ('000), 2002-2010 40Table 26: Cytotoxic Therapies Market, Japan, Treatment Usage Pattern, Population ('000), 2010-2017 41Table 27: Cytotoxic Therapies Market, Global, Breast Cancer, Cancer Categorized by Disease Stage, 2011 44Table 28: Cytotoxic Therapies Market, Global, Breast Cancer, Stage Distribution and Survival For Patients in the US (%), 2001-2007 46Table 29: Cytotoxic Therapies Market, Global, Breast Cancer, Revenue ($m), 2002-2010 50Table 30: Cytotoxic Therapies Market, Global, Breast Cancer, Revenue Forecasts ($m), 2010-2017 50Table 31: Cytotoxic Therapies Market, Global, Breast Cancer, Geographical Segmentation ($m), 2002-2010 51Table 32: Cytotoxic Therapies Market, Global, Breast Cancer, Geographical Segmentation ($m), 2010-2017 52Table 33: Cytotoxic Therapies Market, Global, Breast Cancer, Annual Cost of Therapy ($), 2002-2010 53Table 34: Cytotoxic Therapies Market, Global, Breast Cancer, Annual Cost of Therapy ($), 2010-2017 53Table 35: Cytotoxic Therapies Market, Global, Breast Cancer, Treatment Usage Pattern, Population ('000), 2002-2010 54Table 36: Cytotoxic Therapies Market, Global, Breast Cancer, Treatment Usage Pattern, Population ('000), 2010-2017 55Table 37: Cytotoxic Therapies Market, Global, Cervical Cancer, Clinical Staging, 2011 58Table 38: Cytotoxic Therapies Market, Global, Cervical Cancer, Stage Distribution and Survival For Patients in the US (%), 2001-2007 58Table 39: Cytotoxic Therapies Market, Global, Cervical Cancer, Treatment Flow 59Table 40: Cytotoxic Therapies Market, Global, Cervical Cancer, Revenue ($m), 2002-2010 60Table 41: Cytotoxic Therapies Market, Global, Cervical Cancer, Revenue Forecast ($m), 2010-2017 60Table 42: Cytotoxic Therapies Market, Global, Cervical Cancer, Geographical Segmentation ($m), 2002-2010 61Table 43: Cytotoxic Therapies Market, Global, Cervical Cancer, Geographical Segmentation ($m), 2010-2017 62Table 44: Cytotoxic Therapies Market, Global, Cervical Cancer, Annual Cost of Therapy ($), 2002-2010 63Table 45: Cytotoxic Therapies Market, Global, Cervical Cancer, Annual Cost of Therapy ($), 2010-2017 63Table 46: Cytotoxic Therapies Market, Global, Cervical Cancer, Treatment Usage Pattern, Population ('000), 2002-2010 64Table 47: Cytotoxic Therapies Market, Global, Cervical Cancer, Treatment Usage Pattern, Population ('000), 2010-2017 65Table 48: Cytotoxic Therapies Market, Global, Colorectal Cancer, Cancer Categorized by Disease Stage 68Table 49: Cytotoxic Therapies Market, Global, Colorectal Cancer, Stage Distribution and Five-Year Relative Survival by Stage at Diagnosis for Patients in the US (%), 2001-2007 68Table 50: Cytotoxic Therapies Market, Global, Colorectal Cancer, Revenue ($bn), 2002-2010 72Table 51: Cytotoxic Therapies Market, Global, Colorectal Cancer, Revenue Forecasts ($bn), 2010-2017 72Table 52: Cytotoxic Therapies Market, Global, Colorectal Cancer, Geographical Segmentation ($m), 2002-2010 73Table 53: Cytotoxic Therapies Market, Global, Colorectal Cancer, Geographical Segmentation ($m), 2010-2017 74Table 54: Cytotoxic Therapies Market, Global, Colorectal Cancer, Annual Cost of Therapy ($), 2002-2010 75Table 55: Cytotoxic Therapies Market, Global, Colorectal Cancer, Annual Cost of Therapy ($), 2010-2017 75Table 56: Cytotoxic Therapies Market, Global, Colorectal Cancer, Treatment Usage Pattern, Population ('000), 2002-2010 77Table 57: Cytotoxic Therapies Market, Global, Colorectal Cancer, Treatment Usage Pattern, Population ('000), 2010-2017 77Table 58: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Staging, 2011 79Table 59: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Stage Distribution and Survival For Patients in the US (%), 1998-2001 80Table 60: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Revenue ($m), 2002-2010 82Table 61: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Revenue Forecasts ($m), 2010-2017 82Table 62: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Geographical Segmentation ($m), 2002-2010 84Table 63: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Geographical Segmentation ($m), 2010-2017 84Table 64: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Annual Cost of Therapy ($), 2002-2010 86Table 65: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Annual Cost of Therapy ($), 2010-2017 86Table 66: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Treatment Usage Pattern, Population ('000), 2002-2010 87Table 67: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Treatment Usage Pattern, Population ('000), 2010-2017 88Table 68: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Cancer Categorized by Disease Stage 90Table 69: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Stage Distribution and 5-Year Survival Rates by Stage at Diagnosis for Patients in the US (%), 2001-2007 91Table 70: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Revenue ($m), 2002-2010 93Table 71: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Revenue Forecasts ($m), 2010-2017 93Table 72: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Geographical Segmentation ($m), 2002-2010 94Table 73: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Geographical Segmentation ($m), 2010-2017 95Table 74: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Annual Cost of Therapy ($), 2002-2010 96Table 75: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Annual Cost of Therapy ($), 2010-2017 96Table 76: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Treatment Usage Pattern, Population ('000), 2002-2010 97Table 77: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Treatment Usage Pattern, Population ('000), 2010-2017 98Table 78: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Cancer Categorized by Disease Stage 100Table 79: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Stage Distribution and Survival for Lung Cancer Patients in the US (%), 2000-2007 101Table 80: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Revenue ($m), 2002-2010 104Table 81: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Revenue Forecasts ($m), 2010-2017 104Table 82: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Geographical Segmentation ($m), 2002-2010 105Table 83: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Geographical Segmentation ($m), 2010-2017 106Table 84: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Annual Cost of Therapy ($), 2002-2010 107Table 85: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Annual Cost of Therapy ($), 2010-2017 107Table 86: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Treatment Usage Pattern, Population ('000), 2002-2010 108Table 87: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Treatment Usage Pattern, Population ('000), 2010-2017 109Table 88: Cytotoxic Therapies Market, Global, Ovarian Cancer, Surgical Staging, 2011 111Table 89: Cytotoxic Therapies Market, Global, Ovarian Cancer, Stage Distribution and Survival for Patients in the US (%), 2001-2007 111Table 90: Cytotoxic Therapies Market, Global, Ovarian Cancer, Post-Operative Treatment, 2011 112Table 91: Cytotoxic Therapies Market, Global, Ovarian Cancer, Revenue ($m), 2002-2010 113Table 92: Cytotoxic Therapies Market, Global, Ovarian Cancer, Revenue Forecasts ($m), 2010-2017 113Table 93: Cytotoxic Therapies Market, Global, Ovarian Cancer, Geographical Segmentation ($m), 2002-2010 114Table 94: Cytotoxic Therapies Market, Global, Ovarian Cancer, Geographical Segmentation ($m), 2010-2017 115Table 95: Cytotoxic Therapies Market, Global, Ovarian Cancer, Annual Cost of Therapy ($), 2002-2010 116Table 96: Cytotoxic Therapies Market, Global, Ovarian Cancer, Annual Cost of Therapy ($), 2010-2017 116Table 97: Cytotoxic Therapies Market, Global, Ovarian Cancer, Treatment Usage Pattern, Population ('000), 2002-2010 117Table 98: Cytotoxic Therapies Market, Global, Ovarian Cancer, Treatment Usage Pattern, Population ('000), 2010-2017 118Table 99: Cytotoxic Therapies Market, Global, Prostate Cancer, Cancer Characterized by Disease Stage 120Table 100: Cytotoxic Therapies Market, Global, Prostate Cancer, Stage Distribution and Survival for Patients in the US (%), 2000-2007 121Table 101: Cytotoxic Therapies Market, Global, Prostate Cancer, Revenue ($m), 2002-2010 123Table 102: Cytotoxic Therapies Market, Global, Prostate Cancer, Revenue Forecasts ($m), 2010-2017 124Table 103: Cytotoxic Therapies Market, Global, Prostate Cancer, Geographical Segmentation ($m), 2002-2010 125Table 104: Cytotoxic Therapies Market, Global, Prostate Cancer, Geographical Segmentation ($m), 2010-2017 125Table 105: Cytotoxic Therapies Market, Global, Prostate Cancer, Annual Cost of Therapy ($), 2002-2010 127Table 106: Cytotoxic Therapies Market, Global, Prostate Cancer, Annual Cost of Therapy ($), 2010-2017 128Table 107: Cytotoxic Therapies Market, Global, Prostate Cancer Treatment Usage Pattern, Population ('000), 2002-2010 129Table 108: Cytotoxic Therapies Market, Global, Prostate Cancer Treatment Usage Pattern, Population ('000), 2010-2017 129Table 109: Cytotoxic Therapies Market, Global, Breast Cancer, Phase III Pipeline, 2011 134Table 110: Cytotoxic Therapies Market, Global, Breast Cancer, Phase II Pipeline, 2011 134Table 111: Cytotoxic Therapies Market, Global, Breast Cancer, Phase I Pipeline, 2011 135Table 112: Cytotoxic Therapies Market, Global, Breast Cancer, Pre-Clinical Phase Pipeline, 2011 136Table 113: Cytotoxic Therapies Market, Global, Breast Cancer, Discovery Phase Pipeline, 2011 136Table 114: Cytotoxic Therapies Market, Global, Cervical Cancer, Phase III Pipeline, 2011 137Table 115: Cytotoxic Therapies Market, Global, Cervical Cancer, Phase II Pipeline, 2011 137Table 116: Cytotoxic Therapies Market, Global, Cervical Cancer, Phase I Pipeline, 2011 138Table 117: Cytotoxic Therapies Market, Global, Cervical Cancer, Pre-Clinical Phase Pipeline, 2011 138Table 118: Cytotoxic Therapies Market, Global, Colorectal Cancer, Phase III Pipeline, 2011 139Table 119: Cytotoxic Therapies Market, Global, Colorectal Cancer, Phase II Pipeline, 2011 139Table 120: Cytotoxic Therapies Market, Global, Colorectal Cancer, Phase I Pipeline, 2011 141Table 121: Cytotoxic Therapies Market, Global, Colorectal Cancer, Pre-Clinical Phase Pipeline, 2011 142Table 122: Cytotoxic Therapies Market, Global, Colorectal Cancer, Discovery Phase Pipeline, 2011 142Table 123: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Phase III Pipeline, 2011 144Table 124: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Phase II Pipeline, 2011 144Table 125: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Phase I Pipeline, 2011 145Table 126: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Pre-Clinical Phase Pipeline, 2011 145Table 127: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Phase III Pipeline, 2011 146Table 128: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Phase II Pipeline, 2011 147Table 129: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Phase I Pipeline, 2011 148Table 130: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Phase III Pipeline, 2011 150Table 131: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Phase II Pipeline, 2011 151Table 132: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Phase I Pipeline, 2011 151Table 133: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Pre-Clinical Phase Pipeline, 2011 152Table 134: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Discovery Phase Pipeline, 2011 152Table 135: Cytotoxic Therapies Market, Global, Ovarian Cancer, Phase III Pipeline, 2011 154Table 136: Cytotoxic Therapies Market, Global, Ovarian Cancer, Phase II Pipeline, 2011 155Table 137: Cytotoxic Therapies Market, Global, Ovarian Cancer, Phase I Pipeline, 2011 157Table 138: Cytotoxic Therapies Market, Global, Ovarian Cancer, Pre-Clinical Phase Pipeline, 2011 158Table 139: Cytotoxic Therapies Market, Global, Ovarian Cancer, Discovery Phase Pipeline, 2011 159Table 140: Cytotoxic Therapies Market, Global, Prostate Cancer, Phase III Pipeline, 2011 160Table 141: Cytotoxic Therapies Market, Global, Prostate Cancer, Phase II Pipeline, 2011 160Table 142: Cytotoxic Therapies Market, Global, Prostate Cancer, Phase I Pipeline, 2011 161Table 143: Cytotoxic Therapies Market, Global, Prostate Cancer, Pre-Clinical Phase Pipeline, 2011 161Table 144: Cytotoxic Therapies Market, Global, M&A Deals, 2008-2011 180Table 145: Cytotoxic Therapies Market, Global, Co-Development Deals, 2008-2011 184Table 146: Cytotoxic Therapies Market, Global, Licensing Deals, 2008-2011 189

1.2 List of Figures

Figure 1: Cytotoxic Therapies Market, Global, Revenue Forecasts ($bn), 2002-2017 16Figure 2: Cytotoxic Therapies Market, Global, Branded and Generic Market Share (%), 2010 and 2017 17Figure 3: Cytotoxic Therapies Market, Global, Annual Cost of Therapy ($), 2002-2017 19Figure 4: Cytotoxic Therapies Market, Global, Treatment Usage Pattern, Population ('000), 2002-2017 20Figure 5: Cytotoxic Therapies Market, Global, Drivers and Barriers 22Figure 6: Cytotoxic Therapies Market, Global, Geographical Segmentation ($m), 2002-2017 24Figure 7: Cytotoxic Therapies Market, The US, Revenue Forecasts ($bn), 2002-2017 26Figure 8: Cytotoxic Therapies Market, The US, Annual Cost of Therapy ($), 2002-2017 27Figure 9: Cytotoxic Therapies Market, The US, Treatment Usage Pattern, Population ('000), 2002-2017 28Figure 10: Cytotoxic Therapies Market, The US, Drivers and Barriers 30Figure 11: Cytotoxic Therapies Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2002-2017 32Figure 12: Cytotoxic Therapies Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2002-2017 33Figure 13: Cytotoxic Therapies Market, Top Five Countries of Europe, Treatment Usage Pattern, Population ('000), 2002-2017 34Figure 14: Cytotoxic Therapies Market, Top Five Countries of Europe, Drivers and Barriers 36Figure 15: Cytotoxic Therapies Market, Japan, Revenue Forecasts ($m), 2002-2017 38Figure 16: Cytotoxic Therapies Market, Japan, Annual Cost of Therapy ($), 2002-2017 39Figure 17: Cytotoxic Therapies Market, Japan, Treatment Usage Pattern, Population ('000), 2002-2017 40Figure 18: Cytotoxic Therapies Market, Japan, Drivers and Barriers 42Figure 19: Cytotoxic Therapies Market, Global, Breast Cancer, Types of Breast Cancer, 2011 45Figure 20: Cytotoxic Therapies Market, Global, Breast Cancer, Treatment Flow Algorithm, Stage 0 47Figure 21: Cytotoxic Therapies Market, Global, Breast Cancer, Treatment Flow Algorithm, Stage I and II 47Figure 22: Cytotoxic Therapies Market, Global, Breast Cancer, Treatment Flow Algorithm, Stage III 48igure 23: Cytotoxic Therapies Market, Global, Breast Cancer, Treatment Flow Algorithm, Stage IV 48Figure 24: Cytotoxic Therapies Market, Global, Breast Cancer, Revenue Forecasts ($m), 2002-2017 50Figure 25: Cytotoxic Therapies Market, Global, Breast Cancer, Geographical Segmentation ($m), 2002-2017 51Figure 26: Cytotoxic Therapies Market, Global, Breast Cancer, Branded and Generic Market Share (%), 2010 and 2017 52Figure 27: Cytotoxic Therapies Market, Global, Breast Cancer, Annual Cost of Therapy ($), 2002-2017 53Figure 28: Cytotoxic Therapies Market, Global, Breast Cancer, Treatment Usage Pattern, Population ('000), 2002-2017 54Figure 29: Cytotoxic Therapies Market, Global, Breast Cancer, Drivers and Barriers 56Figure 30: Cytotoxic Therapies Market, Global, Cervical Cancer, Revenue Forecasts ($m), 2002-2017 60Figure 31: Cytotoxic Therapies Market, Global, Cervical Cancer, Geographical Segmentation ($m), 2002-2017 61Figure 32: Cytotoxic Therapies Market, Global, Cervical Cancer, Branded and Generic Market Share (%), 2010 and 2017 62Figure 33: Cytotoxic Therapies Market, Global, Cervical Cancer, Annual Cost of Therapy ($), 2002-2017 63Figure 34: Cytotoxic Therapies Market, Global, Cervical Cancer, Treatment Usage Pattern, Population ('000), 2002-2017 64Figure 35: Cytotoxic Therapies Market, Global, Cervical Cancer, Drivers and Barriers 66Figure 36: Cytotoxic Therapies Market, Global, Colorectal Cancer, Treatment Flow Algorithm, Colon Cancer, Part-1 69Figure 37: Cytotoxic Therapies Market, Global, Colorectal Cancer, Treatment Flow Algorithm, Colon Cancer, Part-2 70Figure 38: Cytotoxic Therapies Market, Global, Colorectal Cancer, Treatment Flow Algorithm, Rectal Cancer, 2011 71Figure 39: Cytotoxic Therapies Market, Global, Colorectal Cancer, Revenue Forecasts ($bn), 2002-2017 72Figure 40: Cytotoxic Therapies Market, Global, Colorectal Cancer, Geographical Segmentation ($m), 2002-2017 73Figure 41: Cytotoxic Therapies Market, Global, Colorectal Cancer, Branded and Generic Market Share (%), 2010 and 2017 74Figure 42: Cytotoxic Therapies Market, Global, Colorectal Cancer, Annual Cost of Therapy ($), 2002-2017 75Figure 43: Cytotoxic Therapies Market, Global, Colorectal Cancer, Treatment Usage Pattern, Population ('000), 2002-2017 76Figure 44: Cytotoxic Therapies Market, Global, Colorectal Cancer, Drivers and Barriers 78Figure 45: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Treatment Flow Algorithm 81Figure 46: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Revenue Forecasts ($m), 2002-2017 82Figure 47: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Geographical Segmentation ($m), 2002-2017 83Figure 48: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Branded and Generic Market Share (%), 2010 and 2017 85Figure 49: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Annual Cost of Therapy ($), 2002-2017 86Figure 50: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Treatment Usage Pattern, Population ('000), 2002-2017 87Figure 51: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Drivers and Barriers 89Figure 52: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Classification 91Figure 53: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Treatment Flow Algorithm 92Figure 54: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Revenue Forecasts ($m), 2002-2017 93Figure 55: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Geographical Segmentation ($m), 2002-2017 94Figure 56: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Branded and Generic Market Share (%), 2010 and 2017 95Figure 57: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Annual Cost of Therapy ($), 2002-2017 96Figure 58: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Treatment Usage Pattern, Population ('000), 2002-2017 97Figure 59: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Drivers and Barriers 99Figure 60: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Treatment Flow Algorithm, Part 1 102Figure 61: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Treatment Flow Algorithm, Part 2 103Figure 62: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Revenue Forecasts ($m), 2002-2017 104Figure 63: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Geographical Segmentation ($m), 2002-2017 105Figure 64: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Branded and Generic Market Share (%), 2010 and 2017 106Figure 65: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Annual Cost of Therapy ($), 2002-2017 107Figure 66: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Treatment Usage Pattern, Population ('000), 2002-2017 108Figure 67: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Drivers and Barriers 110Figure 68: Cytotoxic Therapies Market, Global, Ovarian Cancer, Revenue Forecasts ($m), 2002-2017 113Figure 69: Cytotoxic Therapies Market, Global, Ovarian Cancer, Geographical Segmentation ($m), 2002-2017 114Figure 70: Cytotoxic Therapies Market, Global, Ovarian Cancer, Branded and Generic Market Share (%), 2010 and 2017 115Figure 71: Cytotoxic Therapies Market, Global, Ovarian Cancer, Annual Cost of Therapy ($), 2002-2017 116Figure 72: Cytotoxic Therapies Market, Global, Ovarian Cancer, Treatment Usage Pattern, Population ('000), 2002-2017 117Figure 73: Cytotoxic Therapies Market, Global, Ovarian Cancer, Drivers and Barriers 119Figure 74: Cytotoxic Therapies Market, Global, Prostate Cancer, Treatment Flow Algorithm 122Figure 75: Cytotoxic Therapies Market, Global, Prostate Cancer, Revenue Forecasts ($m), 2002-2017 123Figure 76: Cytotoxic Therapies Market, Global, Prostate Cancer, Geographical Segmentation ($m), 2002-2017 124Figure 77: Cytotoxic Therapies Market, Global, Prostate Cancer, Branded and Generic Market Share (%), 2010 and 2017 126Figure 78: Cytotoxic Therapies Market, Global, Prostate Cancer, Annual Cost of Therapy ($), 2002-2017 127Figure 79: Cytotoxic Therapies Market, Global, Prostate Cancer, Treatment Usage Pattern, Population ('000), 2002-2017 128Figure 80: Cytotoxic Therapies Market, Global, Prostate Cancer, Drivers and Barriers, 2011 130Figure 81: Cytotoxic Therapies Market, Global, R&D Pipeline by Indication, 2011 131Figure 82: Cytotoxic Therapies Market, Global, R&D Pipeline by Phase, 2011 132Figure 83: Cytotoxic Therapies Market, Global, Breast Cancer R&D Pipeline, 2011 133Figure 84: Cytotoxic Therapies Market, Global, Cervical Cancer R&D Pipeline, 2011 137Figure 85: Cytotoxic Therapies Market, Global, Colorectal Cancer R&D Pipeline, 2011 138Figure 86: Cytotoxic Therapies Market, Global, Head and Neck Cancer R&D Pipeline, 2011 143Figure 87: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma R&D Pipeline, 2011 146Figure 88: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer R&D Pipeline, 2011 149Figure 89: Cytotoxic Therapies Market, Global, Ovarian Cancer R&D Pipeline, 2011 153Figure 90: Cytotoxic Therapies Market, Global, Prostate Cancer R&D Pipeline, 2011 159Figure 91: Cytotoxic Therapies Market, Competitive Landscape, Sanofi, 2011 167Figure 92: Cytotoxic Therapies Market, Competitive Landscape, Sanofi, SWOT, 2011 168Figure 93: Cytotoxic Therapies Market, Competitive Landscape, Eli Lilly & Company, 2011 169Figure 94: Cytotoxic Therapies Market, Competitive Landscape, Eli Lilly, SWOT, 2011 171Figure 95: Cytotoxic Therapies Market, Competitive Landscape, Takeda Pharmaceuticals, 2011 172Figure 96: Cytotoxic Therapies Market, Competitive Landscape, Takeda, SWOT, 2011 173Figure 97: Cytotoxic Therapies Market, Competitive Landscape, Roche, 2011 174Figure 98: Cytotoxic Therapies Market, Competitive Landscape, Hoffmann-La Roche, SWOT, 2011 175Figure 99: Cytotoxic Therapies Market, Global, Deals by Type, 2008-2011 176Figure 100: Cytotoxic Therapies Market, Global, Deals by Indications, 2008-2011 177Figure 101: Cytotoxic Therapies Market, Global, Mergers and Acquisitions, Segmentation By Year, 2008-2011 178Figure 102: Cytotoxic Therapies Market, Global, Mergers and Acquisitions, Segmentation By Value, 2008-2011 179Figure 103: Cytotoxic Therapies Market, Global, Co-Development Deals, By Indication (%), 2008-2011 181Figure 104: Cytotoxic Therapies Market, Global, Co-Development Deals, Segmentation By Year, 2008-2011 182Figure 105: Cytotoxic Therapies Market, Global, Co-Development Deals, Segmentation By Geography (%), 2008-2011 183Figure 106: Cytotoxic Therapies Market, Global, Licensing Deals, By Indication (%), 2008-2011 185Figure 107: Cytotoxic Therapies Market, Global, Licensing Deals, Segmentation By Year, 2008-2011 186Figure 108: Cytotoxic Therapies Market, Global, Licensing Deals, Segmentation By Value (%), 2008-2011 187Figure 109: Cytotoxic Therapies Market, Global, Licensing Deals, Segmentation By Geography (%), 2008-2011 188Figure 110: GBI Research Market Forecasting Model 197

Companies mentioned

Sanofi

Eli Lilly & Company

Takeda Pharmaceutical Company Ltd.

F. Hoffmann-La Roche Ltd.

To order this report:Pathology Industry: Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion

Market Research Report

Check our

Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker